Abstract
Background
H3 K27M-mutant diffuse midline glioma is a fatal malignancy with no proven medical therapies. The entity predominantly occurs in children and young adults. ONC201 is a small molecule selective antagonist of dopamine receptor D2/3 (DRD2/3) with an exceptional safety profile. Following up on a durable response in the first H3 K27M-mutant diffuse midline glioma patient who received ONC201 (NCT02525692), an expanded access program was initiated.
Methods
Patients with H3 K27M-mutant gliomas who received at least prior radiation were eligible. Patients with leptomeningeal spread were excluded. All patients received open-label ONC201 orally once every week. Safety, radiographic assessments, and overall survival were regularly assessed at least every 8 weeks by investigators. As of August 2018, a total of 18 patients with H3 K27M-mutant diffuse midline glioma or DIPG were enrolled to single patient expanded access ONC201 protocols. Among the 18 patients: seven adult (> 20 years old) and seven pediatric (< 20 years old) patients initiated ONC201 with recurrent disease and four pediatric patients initiated ONC201 following radiation, but prior to disease recurrence.
Findings
Among the 14 patients with recurrent disease prior to initiation of ONC201, median progression-free survival is 14 weeks and median overall survival is 17 weeks. Three adults among the 14 recurrent patients remain on treatment progression-free with a median follow up of 49.6 (range 41–76.1) weeks. Among the 4 pediatric patients who initiated adjuvant ONC201 following radiation, two DIPG patients remain progression-free for at least 53 and 81 weeks. Radiographic regressions, including a complete response, were reported by investigators in a subset of patients with thalamic and pontine gliomas, along with improvements in disease-associated neurological symptoms.
Interpretation
The clinical outcomes and radiographic responses in these patients provide the preliminary, and initial clinical proof-of-concept for targeting H3 K27M-mutant diffuse midline glioma with ONC201, regardless of age or location, providing rationale for robust clinical testing of the agent.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Louis DN, Perry A, Reifenberger G et al (2016) The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820
Solomon DA, Wood MD, Tihan T et al (2016) Diffuse midline gliomas with histone H3–K27M mutation: a series of 47 cases assessing the spectrum of morphologic variation and associated genetic alterations. Brain Pathol 26:569–580
Cohen KJ, Pollack IF, Zhou T et al (2011) Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. Neuro-oncology 13:317–323
Jones C, Karajannis MA, Jones DTW et al (2017) Pediatric high-grade glioma: biologically and clinically in need of new thinking. Neuro-oncology 19:153–161
Li J, Zhu S, Kozono D et al (2014) Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma. Oncotarget 5:882–893
Caragher SP, Hall RR, Ahsan R, Ahmed AU (2018) Monoamines in glioblastoma: complex biology with therapeutic potential. Neuro-oncology 20:1014
Madhukar N, Elemento O, Benes C et al (2016) D2-like dopamine receptor antagonism by ONC201 identified by confluence of computational, receptor binding, and clinical studies. Annual Meeting of the American Association for Cancer Research (AACR)
Allen JE, Krigsfeld G, Mayes PA et al (2013) Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med 5:171–217
Ishida CT, Zhang Y, Bianchetti E et al (2018) Metabolic reprogramming by dual AKT/ERK inhibition through imipridones elicits unique vulnerabilities in glioblastoma. Clin Cancer Res 24:5392–5406
Kline CLB, Van den Heuvel APJ, Allen JE, Prabhu VV, Dicker DT, El-Deiry WS (2016) ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases. Sci Signal 9:ra18
Ishizawa J, Kojima K, Chachad D et al (2016) ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. Sci Signal 9:ra17
Arrillaga-Romany I, Chi AS, Allen JE, Oster W, Wen PY, Batchelor TT (2017) A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma. Oncotarget 8:79298–79304
Stein MN, Bertino JR, Kaufman HL et al (2017) First-in-human clinical trial of oral ONC201 in patients with refractory solid tumors. Clin Cancer Res 23:4163–4169
Chi A, Gardner S, Arrillaga-Romany I et al (2018) ACTR-34. Integrated clinical experience with ONC201 in previously-treated H3 K27M-mutant glioma patients. Neuro-oncology 20:619
Stein MN, Malhotra J, Malhotra U et al (2018) Safety and pharmacodynamics of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration. J Clin Oncol 36:2595
Stein MN, Bertino JR, Kaufman HL et al (2017) First-in-human clinical trial of oral ONC201 in patients with refractory solid tumors. Clin Cancer Res 23:4163
Buczkowicz P, Hoeman C, Rakopoulos P et al (2014) Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat Genet 46:451
The St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome P, Wu G, Diaz AK et al (2014) The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet 46:444
Lewis PW, Müller MM, Koletsky MS et al (2013) Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 340:857–861
Justin N, Zhang Y, Tarricone C et al (2016) Structural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2. Nat Commun 7:11316
Grasso CS, Tang Y, Truffaux N et al (2015) Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nat Med 21:555
Mohammad F, Weissmann S, Leblanc B et al (2017) EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas. Nat Med 23:483
Chheda ZS, Kohanbash G, Okada K et al (2018) Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy. J Exp Med 215:141–157
Wolff JE, Rytting M, Vats T et al (2012) Treatment of recurrent diffuse intrinsic pontine glioma, experience of mdanderson cancer center. J Neurooncol 106:391–397
Wagner J, Kline CL, Zhou L et al (2018) Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment. J Clin Investig 128:2325–2338
Funding
Research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748 to Memorial Sloan Kettering Cancer Center. The funding was provided by Oncoceutics.
Author information
Authors and Affiliations
Contributions
MAK has served as a consultant (medical advisory board) to Bayer over the preceding 2 years.
Corresponding author
Ethics declarations
Conflict of interest
RST, KM, LS, MS, JEA and WO have ownership/employment relationships with Oncoceutics that develops ONC201. LS, MS, WO and MPM serves on the Board of Directors of Oncoceutics. MPM has served as a consultant to Varian, Astra-Zeneca, Celgene, Tocagen, and Abbvie.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Chi, A.S., Tarapore, R.S., Hall, M.D. et al. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201. J Neurooncol 145, 97–105 (2019). https://doi.org/10.1007/s11060-019-03271-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-019-03271-3